)
Visual21 Nov 2025
Data center suppliers
Oncoinvent ASA (BGBIO) investor relations material
Oncoinvent ASA Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary4 Nov, 2025
Executive summary
Completed phase I trials in ovarian and colorectal cancer, with Radspherin showing strong safety and efficacy signals, including a 10% peritoneal recurrence rate at 24 months for ovarian cancer at 7 MBq dose compared to 55-60% in historical controls, and a 28% recurrence rate in colorectal cancer versus 50% in historical controls.
Completed a merger with BerGenBio, resulting in an uplisting to the Oslo Stock Exchange under ticker ONCIN as of 30 October 2025 and a strengthened cash position.
Announced a fully underwritten rights issue of NOK 130 million to support future operations and clinical development.
Presented clinical data at the 15th PSOGI International Congress, confirming the need for novel treatments post-surgery and highlighting engagement with the oncology research community.
Significant events and developments
Finalized merger with BerGenBio, now trading as Oncoinvent ASA on the Oslo main board under ticker ONCIN.
Announced a fully underwritten rights issue of NOK 130 million, with tradable subscription rights and share allocation scheduled through November and December 2025.
Cash runway extended into 2027, combining NOK 45 million existing cash, NOK 45 million from BerGenBio, and NOK 130 million from the rights issue.
Outlook and guidance
First interim data from the phase II ovarian cancer trial expected in the second half of 2026, with full interim results towards the end of 2027 or 2028.
Recruitment for the phase II ovarian cancer study is on track, with 22 of 108 patients recruited by end of September 2025 and additional hospitals joining to accelerate enrollment.
Colorectal cancer program will require external partnership to advance further.
Colorectal cancer data: next steps?
Recruitment acceleration strategy impact?
Phase II interim data: expected impact?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Oncoinvent ASA earnings date
Q4 202526 Feb, 2026
Next Oncoinvent ASA earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BerGenBio ASA is a clinical-stage biopharmaceutical company based in Bergen, Norway, focused on developing innovative therapies for aggressive diseases such as cancer and severe respiratory infections. The company specializes in AXL kinase inhibitors, with its lead product, Bemcentinib, currently undergoing clinical trials for non-small cell lung cancer (NSCLC) and severe respiratory conditions. Another key asset, Tilvestamab, is a monoclonal antibody targeting AXL, being investigated for the treatment of ovarian cancer. BerGenBio is leveraging its expertise in AXL biology to create treatments that can potentially improve outcomes in diseases characterized by drug resistance and immune evasion. The company's strategy includes partnerships with clinical sites and biopharma firms to advance its drug pipeline. The company is headquartered in Bergen, Norway, and its shares are traded on the Oslo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage